• Explore /
  • Poster
  • / A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration resistant prostate cancer (mCRPC).

A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Mary-Ellen Taplin

Dana-Farber Cancer Institute, Boston, MA

Mary-Ellen Taplin , Arif Hussain , Neal D. Shore , Bill Bradley , Patrick Trojer , Claudia Lebedinsky , Adrian Mario Senderowicz , Emmanuel S. Antonarakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr TPS398)

DOI

10.1200/JCO.2018.36.6_suppl.TPS398

Abstract #

TPS398

Poster Bd #

M18

Abstract Disclosures

Similar Posters

First Author: Mary-Ellen Taplin

First Author: Wassim Abida

First Author: Won Kim

Poster

2024 ASCO Genitourinary Cancers Symposium

Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC.

Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC.

First Author: Bobby Chi-Hung Liaw